Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia. It is taken as the sulfate hydrate salt by mouth. Mitapivat...
14 KB (974 words) - 07:12, 14 January 2024
$256 million aggregate gross proceeds. In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with...
7 KB (518 words) - 16:55, 4 May 2024
(i.e., most of the red blood cells are being removed by the spleen). Mitapivat was approved for medical use in the United States in February 2022. Hemolytic...
32 KB (3,557 words) - 12:31, 9 September 2024
spleen. This reduces severe anemia and the need for blood transfusions. Mitapivat was approved for medical use in the United States in February 2022. Pyruvate...
14 KB (1,477 words) - 12:05, 31 October 2024
Crizanlizumab B06AX02 Betibeglogene autotemcel B06AX03 Voxelotor B06AX04 Mitapivat B06AX05 Exagamglogene autotemcel "ATC (Anatomical Therapeutic Chemical...
960 bytes (213 words) - 02:49, 18 December 2023
whether or not a person is a carrier of the mutated gene is also available. Mitapivat (brand name Pyrukynd) may improve symptoms by stimulating pyruvate kinase...
18 KB (1,900 words) - 14:16, 12 October 2024